Therefore, novel targeted and immune-based therapies such as blinatumomab and inotuzumab antibody therapy and chimeric antigen receptor (CAR) T-cell therapies are being explored in this patient group to achieve a cure without unacceptable toxicity. Conclusions: Children with DS are at a significantly ...
5,6 Thus, successful development of novel AML therapy requires not only improved understanding of leukemogenesis but also tolerability of the drug in older patients. Novel drug development strategies are assisted by identification of molecular markers or biologic features of disease associated with ...
Moreover, there is a lack of data concerning academic performance, potential learning disabilities, and supportive therapy such as speech therapy or the use of supportive learning tools. Therefore, this skewed observation might produce inaccurate predictions about the natural neurodevelopmental evolution of...